KR20100087185A - 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체 - Google Patents

항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체 Download PDF

Info

Publication number
KR20100087185A
KR20100087185A KR1020107011577A KR20107011577A KR20100087185A KR 20100087185 A KR20100087185 A KR 20100087185A KR 1020107011577 A KR1020107011577 A KR 1020107011577A KR 20107011577 A KR20107011577 A KR 20107011577A KR 20100087185 A KR20100087185 A KR 20100087185A
Authority
KR
South Korea
Prior art keywords
formula
compound
tetrazol
substituted
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107011577A
Other languages
English (en)
Korean (ko)
Inventor
두르가 프라사드 코나칸치
수바 라오 풀라
락쉬미 아난타네니
레디 무다사니 풀라
칼리 사탸 부장아 라오 아디바틀라
초우다리 난나파네니 벤카이아
Original Assignee
낫코 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 낫코 파마 리미티드 filed Critical 낫코 파마 리미티드
Publication of KR20100087185A publication Critical patent/KR20100087185A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020107011577A 2007-10-29 2008-10-28 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체 Withdrawn KR20100087185A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2445CH2007 2007-10-29
IN2445/CHE/2007 2007-10-29

Publications (1)

Publication Number Publication Date
KR20100087185A true KR20100087185A (ko) 2010-08-03

Family

ID=40433677

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011577A Withdrawn KR20100087185A (ko) 2007-10-29 2008-10-28 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체

Country Status (15)

Country Link
US (1) US8080558B2 (enExample)
EP (1) EP2220054A2 (enExample)
JP (1) JP2011502141A (enExample)
KR (1) KR20100087185A (enExample)
CN (1) CN101878203A (enExample)
AU (1) AU2008320342B2 (enExample)
CA (1) CA2703767A1 (enExample)
EA (1) EA018716B1 (enExample)
GE (1) GEP20125603B (enExample)
MX (1) MX2010004625A (enExample)
MY (1) MY150054A (enExample)
NZ (1) NZ585357A (enExample)
UA (1) UA101168C2 (enExample)
WO (1) WO2009057139A2 (enExample)
ZA (1) ZA201002807B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130729B (zh) * 2011-12-05 2015-07-15 齐鲁制药有限公司 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
WO2014039714A2 (en) * 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN102993114B (zh) * 2012-10-11 2015-08-12 南通市华峰化工有限责任公司 一种1h-四唑-5-乙酸的生产方法
CN103204817B (zh) * 2013-04-16 2018-03-27 江西师范大学 4‑氰基喹唑啉衍生物的制备方法
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JP6704422B2 (ja) 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. キナゾリン誘導体の塩およびその製造方法
CN114787151B (zh) * 2019-11-01 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐、或其药物组合物的用途
JP2023549973A (ja) * 2020-11-23 2023-11-29 エフ． ホフマン－ラ ロシュ アーゲー テトラゾール誘導体の製造のための新規方法
CN114437041B (zh) * 2022-02-25 2023-11-10 湖北科技学院 一类具有抗肿瘤活性的4-四唑基取代-3，4-二氢喹唑啉衍生物及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800039A (en) * 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
AU632992B2 (en) 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
DE3917982A1 (de) 1989-06-02 1990-12-06 Behringwerke Ag Verwendung von xylanpolyhydrogensulfaten zur therapie von zellproliferations-bedingten erkrankungen
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
GB0002040D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
JP2005515176A (ja) 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
PL371587A1 (en) * 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4611745B2 (ja) 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
CN101490016A (zh) * 2006-07-28 2009-07-22 诺瓦提斯公司 作为脂激酶抑制剂的2,4-取代的喹唑啉

Also Published As

Publication number Publication date
AU2008320342A1 (en) 2009-05-07
CA2703767A1 (en) 2009-05-07
US20100261740A1 (en) 2010-10-14
UA101168C2 (ru) 2013-03-11
CN101878203A (zh) 2010-11-03
EA201070543A1 (ru) 2010-12-30
EP2220054A2 (en) 2010-08-25
NZ585357A (en) 2012-02-24
AU2008320342B2 (en) 2012-07-26
JP2011502141A (ja) 2011-01-20
MX2010004625A (es) 2010-05-20
MY150054A (en) 2013-11-29
EA018716B1 (ru) 2013-10-30
WO2009057139A2 (en) 2009-05-07
WO2009057139A3 (en) 2009-09-24
ZA201002807B (en) 2011-07-27
US8080558B2 (en) 2011-12-20
AU2008320342A2 (en) 2010-09-02
GEP20125603B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
AP735A (en) Quinazoline derivatives.
KR20100087185A (ko) 항암제로서의 신규한 4-(테트라졸-5-일)-퀴나졸린 유도체
JP3545763B2 (ja) キナゾリン誘導体及びその抗癌剤としての使用
EP0824527A1 (en) Quinazoline derivatives
ZA200403200B (en) Quinazoline derivatives as antitumor agents.
JP4307843B2 (ja) キナゾリン誘導体
JPH11504031A (ja) キナゾリン誘導体
JPH11504034A (ja) キナゾリン誘導体
JP2010533700A (ja) ピリミジン誘導体
AU778961B2 (en) Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives
US20120172380A1 (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agent
HK1231045A1 (en) Quinazoline derivatives
HK1231045A (en) Quinazoline derivatives
HK1141804A (en) Quinazoline derivatives
HK1042083A (en) Quinazoline derivatives
HK1038740B (en) Quinazoline derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid